Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
Leukoplakia, Hairy, HIV Infections
About this trial
This is an interventional treatment trial for Leukoplakia, Hairy focused on measuring AIDS-Related Opportunistic Infections, Leukoplakia, Oral, Herpesvirus 4, Human, Acyclovir, AIDS-Related Complex
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Topical antifungal therapy. Patient must have: Newly diagnosed clinical and histological hairy leukoplakia. Positive HIV antibody by licensed ELISA or Western blot. Exclusion Criteria Co-existing Condition: Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Concurrent Medication: Excluded within 2 weeks of study entry: Systemic antifungal treatment. Excluded within 6 weeks of study entry: Immunomodulators. Systemic antiviral treatment. Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Prior Medication: Excluded within 2 weeks of study entry: Systemic antifungal. Excluded within 6 weeks of study entry: Immunomodulators. Systemic antiviral treatment. Excluded within 8 weeks of study entry: Zidovudine (AZT) or other antiretroviral therapy.
Sites / Locations
- Univ of Southern California / LA County USC Med Ctr